↓ Skip to main content

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Overview of attention for article published in Experimental Hematology & Oncology, February 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#26 of 171)
  • Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

policy
2 policy sources

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
Published in
Experimental Hematology & Oncology, February 2013
DOI 10.1186/2162-3619-2-5
Pubmed ID
Authors

Stuart Mealing, Leticia Barcena, Neil Hawkins, James Clark, Victoria Eaton, Ishan Hirji, Catherine Davis

Abstract

Dasatinib 100 mg daily and nilotinib 600/800 mg daily have been compared to imatinib as first line treatments for CML in two recent randomised studies. However, no head to head evidence exists of the relative efficacy of dasatinib and nilotinib.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Indonesia 1 2%
Japan 1 2%
Brazil 1 2%
Unknown 52 95%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 9 16%
Other 8 15%
Researcher 7 13%
Student > Ph. D. Student 6 11%
Professor 4 7%
Other 12 22%
Unknown 9 16%
Readers by discipline Count As %
Medicine and Dentistry 24 44%
Agricultural and Biological Sciences 9 16%
Biochemistry, Genetics and Molecular Biology 3 5%
Unspecified 2 4%
Nursing and Health Professions 1 2%
Other 6 11%
Unknown 10 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2017.
All research outputs
#3,486,051
of 17,355,315 outputs
Outputs from Experimental Hematology & Oncology
#26
of 171 outputs
Outputs of similar age
#59,248
of 295,182 outputs
Outputs of similar age from Experimental Hematology & Oncology
#1
of 4 outputs
Altmetric has tracked 17,355,315 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 171 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,182 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them